Trial Profile
An Open-Label, Randomized, Phase 3 Trial of Nivolumab versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Mar 2023
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Carboplatin; Cisplatin; Gemcitabine; Paclitaxel; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms CheckMate 026
- Sponsors Bristol-Myers Squibb; Ono Pharmaceutical
- 19 Dec 2022 This trial has been completed in Italy, according to European Clinical Trials Database record.
- 12 Oct 2022 This trial has been completed in Poland, according to European Clinical Trials Database record.(Global end date 27 May 2022 )
- 19 Jul 2022 Status changed from active, no longer recruiting to completed.